Back to top
more

Allogene Therapeutics (ALLO)

(Real Time Quote from BATS)

$2.90 USD

2.90
1,631,303

+0.07 (2.47%)

Updated Jul 22, 2024 03:55 PM ET

After-Market: $2.90 0.00 (0.00%) 4:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Arvinas, Inc. (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce

by Zacks Equity Research

Once this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022.

Moderna (MRNA) Reports 2023 Business View & Pipeline Updates

by Zacks Equity Research

Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023.

FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA

by Zacks Equity Research

The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.

GSK Signs Deal to Develop Antibodies for Treating Cancer

by Zacks Equity Research

GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

by Zacks Equity Research

Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.

BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA

by Zacks Equity Research

The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.

Down -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a Turnaround

by Zacks Equity Research

Allogene Therapeutics (ALLO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 159%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 158.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 137%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 137.5% upside potential for Allogene Therapeutics (ALLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3

by Zacks Equity Research

Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.

Allogene Therapeutics (ALLO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 6.45% and 45.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy

by Zacks Equity Research

Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 9.09% and 12.33%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Down 10.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well

by Zacks Equity Research

Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.

Allogene Therapeutics (ALLO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 14.75% and 7.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last?

by Zacks Equity Research

Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why Is Allogene Therapeutics (ALLO) Down 14.9% Since Last Earnings Report?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progresses Well

by Zacks Equity Research

Allogene's (ALLO) first-quarter earnings beat estimates. Upon removal of the FDA's clinical hold on its AlloCAR T candidates, ALLO continues to move forward with its pipeline.

Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 5.08% and 39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Is Allogene Therapeutics (ALLO) Up 7.4% Since Last Earnings Report?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.